Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by DIPEN MAHESHBHAI MARU and STEVEN HSESHENG LIN.
DIPEN MAHESHBHAI MARU
Connection Strength
2.304
STEVEN HSESHENG LIN
  1. A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries. Dis Model Mech. 2019 12 17; 12(12).
    View in: PubMed
    Score: 0.177
  2. Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma. Ther Adv Med Oncol. 2019; 11:1758835919864850.
    View in: PubMed
    Score: 0.172
  3. Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma. Oncotarget. 2019 Jul 23; 10(45):4703-4718.
    View in: PubMed
    Score: 0.172
  4. Multi-institutional Analysis of Recurrence and Survival After Neoadjuvant Chemoradiotherapy of Esophageal Cancer: Impact of Histology on Recurrence Patterns and Outcomes. Ann Surg. 2019 04; 269(4):663-670.
    View in: PubMed
    Score: 0.168
  5. Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma. Ann Surg. 2018 08; 268(2):289-295.
    View in: PubMed
    Score: 0.161
  6. Preoperative Nomogram to Risk Stratify Patients for the Benefit of Trimodality Therapy in Esophageal Adenocarcinoma. Ann Surg Oncol. 2018 Jun; 25(6):1598-1607.
    View in: PubMed
    Score: 0.157
  7. The impact of histology on recurrence patterns in esophageal cancer treated with definitive chemoradiotherapy. Radiother Oncol. 2017 08; 124(2):318-324.
    View in: PubMed
    Score: 0.149
  8. Comparative Outcomes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus Intensity Modulated Radiation Therapy for Esophageal Cancer: A Retrospective, Single-Institutional Analysis. Int J Radiat Oncol Biol Phys. 2017 11 01; 99(3):667-676.
    View in: PubMed
    Score: 0.149
  9. Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma. Oncotarget. 2017 Apr 25; 8(17):28696-28710.
    View in: PubMed
    Score: 0.147
  10. Long-term survival and toxicity outcomes of intensity modulated radiation therapy for the treatment of esophageal cancer: A large single-institutional cohort study. Adv Radiat Oncol. 2017 Jul-Sep; 2(3):316-324.
    View in: PubMed
    Score: 0.147
  11. A nomogram that predicts pathologic complete response to neoadjuvant chemoradiation also predicts survival outcomes after definitive chemoradiation for esophageal cancer. J Gastrointest Oncol. 2015 Feb; 6(1):45-52.
    View in: PubMed
    Score: 0.126
  12. Signet ring cells in esophageal adenocarcinoma predict poor response to preoperative chemoradiation. Ann Thorac Surg. 2014 Sep; 98(3):1064-71.
    View in: PubMed
    Score: 0.121
  13. Prolonged neutrophilia is associated with worse outcomes after Esophagectomy. Dis Esophagus. 2022 Apr 19; 35(4).
    View in: PubMed
    Score: 0.052
  14. Salvage Esophagectomy Definition Influences Comparative Outcomes in Esophageal Squamous Cell Cancers. Ann Thorac Surg. 2022 12; 114(6):2032-2040.
    View in: PubMed
    Score: 0.051
  15. Esophageal adenocarcinoma with any component of signet ring cells portends poor prognosis and response to neoadjuvant therapy. J Thorac Cardiovasc Surg. 2021 Nov; 162(5):1404-1412.e2.
    View in: PubMed
    Score: 0.046
  16. Modified En Bloc Esophagectomy Compared With Standard Resection After Neoadjuvant Chemoradiation. Ann Thorac Surg. 2021 04; 111(4):1133-1140.
    View in: PubMed
    Score: 0.046
  17. Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal Cancer. Gastroenterology. 2020 02; 158(3):494-505.e6.
    View in: PubMed
    Score: 0.044
  18. Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience. Cancer. 2017 Nov 01; 123(21):4106-4113.
    View in: PubMed
    Score: 0.038
  19. Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort. Ann Oncol. 2013 May; 24(5):1262-6.
    View in: PubMed
    Score: 0.027
  20. Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation. Oncology. 2012; 83(5):300-4.
    View in: PubMed
    Score: 0.027
  21. A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer. Eur J Cancer. 2012 Dec; 48(18):3396-404.
    View in: PubMed
    Score: 0.026
  22. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. Ann Oncol. 2012 Oct; 23(10):2638-2642.
    View in: PubMed
    Score: 0.026
  23. Nomograms for prognostication of outcome in patients with esophageal and gastroesophageal carcinoma undergoing definitive chemoradiotherapy. Oncology. 2012; 82(2):108-13.
    View in: PubMed
    Score: 0.026
  24. Patients with high body mass index tend to have lower stage of esophageal carcinoma at diagnosis. Dis Esophagus. 2012 Sep-Oct; 25(7):614-22.
    View in: PubMed
    Score: 0.025
  25. Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer. 2011 Nov 01; 117(21):4823-33.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.